Safety profile of bevantolol.
Double-blind and long-term open-label studies have demonstrated a remarkably favorable safety profile for bevantolol. The drug was associated with a low incidence of adverse experiences similar to that observed with placebo. The adverse experiences were mostly mild to moderate and of the types found previously for other beta-blocking drugs. Very few patients withdrew from clinical studies because of adverse effects. Some patients continued on study for over four years. Bevantolol offers safe beta-blocking activity for the long-term treatment of angina and hypertension.
Bray
J S
JS
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007429:Intraocular Pressure / Q000187:drug effects; D010352:Patient Dropouts; D011412:Propanolamines / Q000009:adverse effects* / Q000627:therapeutic use; D011897:Random Allocation; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C021148:bevantolol